ROYALTY PHARMA OA DL-0001

Royalty Pharma’s stock rose to a record high of $60.44 and is trading near its 52-week high after gaining 69% last year. For Q2 2026 the company reported royalties of $768 million (+14%) and portfolio revenues of $773 million (+6%), after which the full-year guidance was raised for the second time. BofA raised its price target to $63.00 and reiterated a “buy” rating, citing strong sales of products such as Tremfya, Voranigo, Imdelltra and Evrysdi. » Plus sur de.investing.com

Royalty Pharma has declared a dividend of US$0.235 per Class A common share for the third quarter of 2026. The payment will be made on 10 September 2026 to shareholders of record at the close of trading on 14 August 2026. The current dividend yield is 1.61%; the company has raised the dividend for six consecutive years. Royalty Pharma invests in biopharmaceutical royalties and recorded a 69% share price increase last year, trading near its 52‑week high of US$58.84. » Plus sur de.investing.com

Royalty Pharma shares reached an all-time high of $56.57; market capitalization is $32.5 billion and the P/E ratio is 29.42. Over the past year the stock delivered a total return of 60%; the dividend has been raised for six consecutive years and the current dividend yield is 1.67%. For Q1 2026 the company reported double‑digit growth in portfolio and license revenues, but did not provide specific EPS or revenue guidance. A fair‑value analysis suggests the stock is trading close to its fair value. » Plus sur de.investing.com